Influence of medical comorbidities on the presentation and outcomes of stage I-III non-small-cell lung cancer

Clinical Lung Cancer

Volumn 14, Issue 6, 2013, Pages 644-650

  Ahn, Daniel H ^a   Mehta, Nishi ^a   Yorio, Jeffrey T ^a   Xie, Yang ^b,c   Yan, Jingsheng ^b,c   Gerber, David E ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Charlson Index; Disparities; Early stage; Locally advanced; Treatment

Indexed keywords

AGE; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; COMORBIDITY; FEMALE; GENDER; HEALTH INSURANCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RACE; RETROSPECTIVE STUDY;

CHARLSON INDEX; DISPARITIES; EARLY STAGE; LOCALLY ADVANCED; TREATMENT;

AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; COMORBIDITY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SEX FACTORS; SOCIOECONOMIC FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84887249927     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.06.009     Document Type: Article

References (41)

1. P.B. Bach, L.D. Cramer, and J.L. Warren Racial differences in the treatment of early-stage lung cancer N Engl J Med 341 1999 1198 1205
2. H.P. Greenwald, N.L. Polissar, and E.F. Borgatta Social factors, treatment, and survival in early-stage non-small cell lung cancer Am J Public Health 88 1998 1681 1684
3. E.R. Park, S.J. Japuntich, and L. Traeger Disparities between blacks and whites in tobacco and lung cancer treatment Oncologist 16 2011 1428 1434
4. C.S. Lathan, B.A. Neville, and C.C. Earle The effect of race on invasive staging and surgery in non-small-cell lung cancer J Clin Oncol 24 2006 413 418
5. E.O. Taiwo, J.T. Yorio, and J. Yan How have we diagnosed early-stage lung cancer without radiographic screening? A contemporary single-center experience PLoS One 7 2012 e52313
6. J.T. Yorio, Y. Xie, and J. Yan Lung cancer diagnostic and treatment intervals in the United States: a health care disparity? J Thorac Oncol 4 2009 1322 1330
7. J.T. Yorio, J. Yan, and Y. Xie Socioeconomic disparities in lung cancer treatment and outcomes persist within a single academic medical center Clin Lung Cancer 13 2012 448 457
8. D.E. Gerber, D.W. Rasco, and P. Le Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy J Thorac Oncol 6 2011 365 371
9. S.K. Pal, and A. Hurria Impact of age, sex, and comorbidity on cancer therapy and disease progression J Clin Oncol 28 2010 4086 4093
10. J.F. Piccirillo, R.M. Tierney, and I. Costas Prognostic importance of comorbidity in a hospital-based cancer registry JAMA 291 2004 2441 2447
11. C.C. Earle, L.N. Venditti, and P.J. Neumann Who gets chemotherapy for metastatic lung cancer? Chest 117 2000 1239 1246
12. T.R. Asmis, K. Ding, and L. Seymour Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials J Clin Oncol 26 2008 54 59
13. D. Moro-Sibilot, A. Aubert, and S. Diab Comorbidities and Charlson score in resected stage I nonsmall cell lung cancer Eur Respir J 26 2005 480 486
14. M. Extermann, J. Overcash, and G.H. Lyman Comorbidity and functional status are independent in older cancer patients J Clin Oncol 16 1998 1582 1587
15. P.C. Albertsen, J.A. Hanley, and D.F. Gleason Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer JAMA 280 1998 975 980
16. A. Fuks, C. Weijer, and B. Freedman A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group J Clin Epidemiol 51 1998 69 79
17. L.F. Hutchins, J.M. Unger, and J.J. Crowley Underrepresentation of patients 65 years of age or older in cancer-treatment trials N Engl J Med 341 1999 2061 2067
18. C.N. Klabunde, L.C. Harlan, and J.L. Warren Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients Med Care 44 2006 921 928
19. M.E. Charlson, P. Pompei, and K.L. Ales A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
20. O. Birim, A.P. Kappetein, and A.J. Bogers Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer Eur J Cardiothorac Surg 28 2005 759 762
21. C.Y. Wang, Y.S. Lin, and C. Tzao Comparison of Charlson comorbidity index and Kaplan-Feinstein index in patients with stage I lung cancer after surgical resection Eur J Cardiothorac Surg 32 2007 877 881
22. O. Birim, A.P. Maat, and A.P. Kappetein Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer Eur J Cardiothorac Surg 23 2003 30 34
23. US Census Bureau. State and County QuickFacts 2010. Available at: http://quickfacts.census.gov/qfd/index.html. Accessed: April 10, 2013.
24. R.J. Battafarano, J.F. Piccirillo, and B.F. Meyers Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer J Thorac Cardiovasc Surg 123 2002 280 287
25. A.K. Ganti, E. Siedlik, and A.S. Marr Predictive ability of Charlson comorbidity index on outcomes from lung cancer Am J Clin Oncol 34 2011 593 596
26. P.A. Groome, V. Bolejack, and J.J. Crowley The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours J Thorac Oncol 2 2007 694 705
27. J.A. Blanco, I.S. Toste, and R.F. Alvarez Age, comorbidity, treatment decision and prognosis in lung cancer Age Ageing 37 2008 715 718
28. S. Firat, A. Pleister, and R.W. Byhardt Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III nonsmall cell lung cancer (NSCLC) Am J Clin Oncol 29 2006 252 257
29. F. Farjah, D.E. Wood, and T.K. Varghese Health care utilization among surgically treated Medicare beneficiaries with lung cancer Ann Thorac Surg 88 2009 1749 1756
30. L. Lee, W.Y. Cheung, and E. Atkinson Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review J Clin Oncol 29 2011 106 117
31. V. Mehta Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention Int J Radiat Oncol Biol Phys 63 2005 5 24
32. G. Frasci, V. Lorusso, and N. Panza Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer J Clin Oncol 18 2000 2529 2536
33. W.L. Read, R.M. Tierney, and N.C. Page Differential prognostic impact of comorbidity J Clin Oncol 22 2004 3099 3103
34. K.S. Albain, J.M. Unger, and J.J. Crowley Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group J Natl Cancer Inst 101 2009 984 992
35. C.S. Dela Cruz, L.T. Tanoue, and R.A. Matthay Lung cancer: epidemiology, etiology, and prevention Clin Chest Med 32 2011 605 644
36. S. Cykert, P. Dilworth-Anderson, and M.H. Monroe Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer JAMA 303 2010 2368 2376
37. C.R. Mulligan, A.D. Meram, and C.D. Proctor Unlimited access to care: effect on racial disparity and prognostic factors in lung cancer Cancer Epidemiol Biomarkers Prev 15 2006 25 31
38. D.R. Aberle, A.M. Adams, and C.D. Berg Reduced lung-cancer mortality with low-dose computed tomographic screening N Engl J Med 365 2011 395 409
39. C.M. Tammemagi, C. Neslund-Dudas, and M. Simoff Impact of comorbidity on lung cancer survival Int J Cancer 103 2003 792 802
40. P. Maione, F. Perrone, and C. Gallo Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study J Clin Oncol 23 2005 6865 6872
41. H. Quan, G.A. Parsons, and W.A. Ghali Validity of information on comorbidity derived from ICD-9-CCM administrative data Med Care 40 2002 675 685